<DOC>
	<DOCNO>NCT02910635</DOCNO>
	<brief_summary>The primary objective study ass correct QT interval ( QTc ) effect volanesorsen ( ISIS 304801 ) administer 300 mg subcutaneous ( SC ) therapeutic 300 mg intravenous ( IV ; 2-hour infusion ) supra-therapeutic dose relative placebo healthy adult male female subject .</brief_summary>
	<brief_title>A Study Evaluate Effect Volanesorsen Cardiac Repolarization Conducted Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Abnormalities</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Must give write informed consent able comply study requirement Males female age 1855 time inform consent Females must nonpregnant nonlactating surgically sterile , postmenopausal engage sexual relation childbearing potential , use acceptable contraceptive method Males must surgically sterile , abstinent use acceptable contraceptive method The subject BMI 19 32 kg/m^2 inclusive Consumption nicotine nicotinecontaining product least 6 month Screening History risk factor Torsades de Pointes , unexplained syncope , know Long QT Syndrome , heart failure , myocardial infarction , angina , clinical significant abnormal laboratory assessment include hypokalemia , hypocalcemia , hypercalcemia , hypomagnesemia Abnormal screening ECG Use concomitant medication unless authorize Sponsor Medical Monitor Known history positive test human immunodeficiency virus ( HIV ) , hepatitis C chronic hepatitis B Treatment another Study Drug , biological agent , device within onemonth Screening Tests positive drug abuse cotinine Considered unsuitable inclusion Principal Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Thorough QTc , Therapeutic dose , supra therapeutic dose</keyword>
</DOC>